Short answer
Nuvectis Pharma, Inc. (NVCT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$30M
- −303.0% YoY · −328.3% QoQ
- EPS (diluted)
- −$1.13
- −151.1% YoY · −276.7% QoQ
Source: XBRL data from the Nuvectis Pharma, Inc. (NVCT) Q3 2026 10-Q on SEC EDGAR. USD.
Nuvectis Pharma, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product revenue since inception
- Net loss $30.1M vs $7.5M YoY, operating loss $31.0M vs $7.8M
- Worst performer: NXP100, NXP200 and NXP900 development drove R&D $27.4M vs $5.8M
- Cash $140.7M, operating cash use $36.3M, financing cash inflow $145.4M
- Outlook: cash expected to fund operations through at least 12 months, additional capital required long term
Risk Factors
- New risk: U.S. trade-policy changes affecting China-originated NXP100 and NXP200 materials, technology, and clinical data
- New risk: Tariffs could increase research costs, although no tariffs affected operations as of September 30, 2026
- Regulatory risk: One Big Beautiful Bill Act FDA workforce reductions could delay product approvals
- Operational risk: Dependence on Haisco for NXP100 and NXP200 technology transfer and material supply
- Financial risk: Accumulated deficit reached $142.8 million through September 30, 2026, requiring substantial additional funding
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvectis Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.